Risk Factors, Coronary Severity, Outcome and ABO Blood Group

A Large Chinese Han Cohort Study

Yan Zhang, MD, Sha Li, MD, Cheng-Gang Zhu, MD, Yuan-Lin Guo, MD, Na-Qiong Wu, MD, Rui-Xia Xu, PhD, Qian Dong, MS, Geng Liu, MS, and Jian-Jun Li, MD, PhD

Abstract: ABO blood type locus has been reported to have ethnic difference and to be a pivotal genetic determinant of cardiovascular risk, whereas few prospective data regarding the impact on cardiovascular outcomes are available in a large cohort of patients with angiography-proven coronary artery disease, especially from the Chinese population. The objective of this study was to assess the prognostic role of blood type in future cardiovascular events (CVEs) in Chinese Han patients undergoing coronary angiography.

The population of this prospective cohort study consisted of 3823 eligible patients, and followed annually to capture all CVEs. Baseline characteristics and ABO blood type were obtained. Cox proportional hazards models were used to evaluate the risk of ABO blood type on CVEs.

New CVEs occurred in 348 patients [263 (10.3%) non-O and 85 (7.8%) O] during a median period of 24.6 months follow-up. Significantly, non-O blood group was related to the presence and severity of coronary atherosclerosis and several risk factors including inflammatory markers. The log-rank test revealed that there was a significant difference between non-O and O blood groups in event-free survival analysis (P = 0.026). In particular, the Cox proportional hazards models revealed that non-O blood type was associated with increased CVEs risk [hazard ratio (95% confidence interval) 1.320 (1.033–1.685)], even after adjusting for potential confounders [adjusted hazard ratio (95% confidence interval) non-O: 1.289 (1.003–1.656); A: 1.083 (0.797–1.472); B: 1.481 (1.122–1.955); AB: 1.249 (0.852–1.831), respectively].

Non-O blood type is associated with future CVEs in Chinese Han patients undergoing coronary angiography.

INTRODUCTION

After its first description in 1901, the ABO blood group system has been of immense interest more than a century. The ABO gene locus has been mapped to chromosome 9 at locus 9q34.1 The antigens (A, B, and H determinants) have been shown to consist of complex carbohydrate molecules, which are traditionally regarded as placed on the extracellular surface of the red blood cell membranes, are actually expressed on a variety of human tissues, including epithelium, sensory neurons, platelets, and vascular endothelium.2 The ABO blood group system was the first genetic polymorphism discovered in humans.3 Thus, research on ABO group system has been of great interest, because of its medical importance in different diseases.4,5

ABO blood groups, in particular non-O blood groups, have been suggested to be associated with several cardiovascular risk factors,6 and even a higher risk of ischemic heart disease (IHD), cerebral ischemia of arterial origin, and of developing severe manifestations of atherosclerosis.7 Although several cross-sectional studies including the data from our group have revealed the relation between non-O blood group and an increased coronary artery disease (CAD) risk,8–10 prospective data remain controversial.11–13 The evidences based on large-scale general population supported that non-O blood type have higher risk of developing CAD1 and increased cardiovascular mortality.14 A study involving patients from the Netherlands who underwent major vascular surgery, however, did not find any relationship between ABO blood groups and cardiovascular mortality during 4 years follow-up.15 Moreover, a 10 years follow-up study from Italy proved that non-O blood group increased the risk for cardiac death in non-elderly patients undergoing coronary angiography.14 In addition, it has been well accepted that the distribution of ABO blood groups are distinct in different ethnic population.15 Thus, the possible reasons for the discrepancy may be because of the diversity of enrolled population and ethnic difference of these studies.

In this follow-up investigation regarding a large cohort of Chinese Han patients who underwent coronary angiography (n = 3823), we sought to address the relationship of ABO blood group with cardiovascular risk factors, the association between
ABO blood group and the CAD incidence and severity, and the value of ABO blood group in predicting future cardiovascular events (CVEs).

METHODS

Patients
The study protocol was approved by the hospital’s ethical review board (Fuwai Hospital and National Center for Cardiovascular Diseases, Beijing, China) and complied with the Declaration of Helsinki. The informed written consent was obtained from each patient. In the current cohort study, a total of 3823 Chinese Han patients were enrolled through March 2011 to April 2014. Patients newly referred to our institution with clinically suspected or known coronary atherosclerosis scheduled for selective coronary angiography were prospectively recruited and enrolled. All the enrolled patients have a detailed clinical, laboratory data, and well-documented traditional cardiovascular risk factors. Exclusion criteria included active cardiopulmonary diseases and serious systemic diseases, such as serious acute left heart failure, severe trauma, significant hematologic disorders, infectious or systemic inflammatory disease within 1 month, severe liver (aspartate aminotransferase or alanine aminotransferase 3 times more than the upper normal limits) and/or renal insufficiency (blood creatinine >132 μmol/L), and malignant disease on the baseline. The flowchart of our sample enrollment is shown in Supplemental Figure 1 http://links.lww.com/MD/A479.

TABLE 1. Baseline Characteristics of the Study Population According to the Occurrence of Events

| Demographic Characteristics                      | Events (n = 348) | No Events (n = 3306) | P Value |
|-------------------------------------------------|-----------------|---------------------|---------|
| Demographic Characteristics                      |                 |                     |         |
| Age (years)                                      | 59.4 (9.8)      | 57.7 (9.9)          | 0.003   |
| Male sex, n (%)                                  | 252 (72.4)      | 2321 (70.2)         | 0.422   |
| Body mass index, (kg/m²)                         | 25.7 (3.1)      | 25.7 (3.2)          | 0.620   |
| Current smoking status, n (%)                    | 187 (53.8)      | 1732 (52.4)         | 0.651   |
| Current alcohol intake, n (%)                    | 101 (28.9)      | 843 (25.5)          | 0.175   |
| Medical History, n (%)                           |                 |                     |         |
| History of hypertension                          | 250 (71.8)      | 2023 (61.2)         | <0.001  |
| History of diabetes                              | 114 (32.7)      | 840 (25.4)          | 0.005   |
| History of dyslipidemia                          | 271 (78.0)      | 2446 (74.0)         | 0.120   |
| Previous PCI or CABG                             | 86 (24.7)       | 691 (20.9)          | 0.099   |
| Family history of CAD                            | 51 (14.7)       | 522 (15.8)          | 0.759   |
| Incident CAD, n (%)                              | 341 (98.0)      | 2845 (86.1)         | <0.001  |
| LM diseased                                      | 53 (15.7)       | 269 (8.3)           | <0.001  |
| 1 vessel diseased                                | 67 (19.5)       | 861 (26.3)          | 0.006   |
| 2 vessels diseased                               | 104 (30.2)      | 925 (28.2)          | 0.437   |
| 3 vessels diseased                               | 166 (48.3)      | 1007 (30.7)         | <0.001  |
| Cardiac Parameters                               |                 |                     |         |
| Resting heart rate (bpm)                         | 70 (9)          | 70 (8)              | 0.270   |
| Systolic blood pressure (mm Hg)                  | 125 (15)        | 125 (16)            | 0.741   |
| Diastolic blood pressure (mm Hg)                 | 76 (10)         | 76 (10)             | 0.201   |
| Fasting glucose (mmol/L)                         | 5.90 (1.97)     | 5.59 (1.61)         | 0.001   |
| TC (mmol/L)                                      | 4.25 (1.14)     | 4.19 (1.11)         | 0.373   |
| TG (mmol/L)                                      | 1.94 (1.91)     | 1.78 (1.12)         | 0.112   |
| LDL-C (mmol/L)                                   | 2.53 (0.91)     | 2.53 (0.97)         | 0.967   |
| HDL-C (mmol/L)                                   | 1.07 (0.28)     | 1.08 (0.29)         | 0.480   |
| ABO type, n (%)                                  |                 |                     | 0.017   |
| O                                                | 85 (7.8)        | 1010 (92.2)         |         |
| A                                                | 86 (8.9)        | 883 (91.1)          |         |
| B                                                | 138 (11.5)      | 1057 (88.5)         |         |
| AB                                               | 39 (9.9)        | 356 (90.1)          |         |
| O/non-O group, n (%)                             |                 |                     | 0.019   |
| O                                                | 85 (7.8)        | 1010 (92.2)         |         |
| non-O                                           | 263 (10.3)      | 2296 (89.7)         |         |
| Cardiovascular Medication Use, n (%)             |                 |                     |         |
| ACEI                                            | 50 (14.5)       | 364 (11.0)          | 0.228   |
| ARB                                             | 54 (15.4)       | 410 (12.4)          | 0.385   |
| β-blockers                                       | 183 (52.5)      | 1689 (51.1)         | 0.775   |
| Statins                                         | 221 (63.5)      | 2205 (66.7)         | 0.321   |

Data are expressed as mean (standard deviation) or n (%). ACEI = angiotensin-converting enzyme inhibitors, ARB = angiotensin-receptor blocker, CABG = coronary artery bypass grafting, CAD = coronary artery disease, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, LM = left main coronary artery, PCI = percutaneous coronary intervention; TC = total cholesterol, TG = triglyceride.
The definitions of traditional cardiovascular risk factors have been described in our previous studies. Dyslipidemia was defined as fasting total cholesterol ≥ 5.1 mmol/L or triglyceride ≥ 1.70 mmol/L or the use of lipid-modulating medications. Hypertension was defined as repeated blood pressure measurements ≥ 140/90 mm Hg (at least 2 times in different environments) or currently taking antihypertensive drugs. The definition of diabetes mellitus (DM) was fasting serum glucose level ≥ 7.0 mmol/L in multiple determinations, or the currently use of medications. Patients with a reported smoking habit of at least 1 cigarette per day were classified as current smokers.

Biochemical Analyses

At baseline, fasting whole blood samples were obtained from a vein in the antecubital fossa and were collected in precooled ethylenediaminetetraacetic acid tubes from each patient. The ABO blood groups were determined by standard procedures using agglutination techniques as we previously indicated. The concentrations of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were analyzed by selective solubilization method (LDL-C or HDL-C kit, Kyowa Medex, Tokyo). All of the lipid profiles were determined by automatic biochemistry analyzer (Hitachi 7150, Tokyo, Japan). The high sensitivity-C reactive protein (hs-CRP) concentrations were determined by immunoturbidimetry (Beckmann Assay, Bera, CA). The erythrocyte sedimentation rate (ESR) was analyzed by Westergren method. The fibrinogen levels were measured by the Stago auto analyzer using Clauss method (Diagnostic Stago, Taverny, France). White blood cell counts were determined by the automated hematology analyzer (Sysmex XE-1200, Kobe, Japan).

Gensini Score Calculation

All the angiographic data were collected for each patient, and the severity of coronary atherosclerosis was calculated by the Gensini score system by assigning a severity score to each coronary stenosis according to the degree of luminal narrowing (the score was given from 1 to 32) and its geographic importance (the score was given from 0.5 to 5). A detailed description of the calculation method has been published previously.

Outcome Measurement

Follow-up data were obtained via standardized telephone interviews conducted by study nurses who were blinded to the aim of this study, after 6, 12, 24, 36, 48, and 60 months.
patients reported that they had been hospitalized, appropriate hospital records were consulted. The primary endpoints were the composite of death, nonfatal acute myocardial infarction, unstable angina need for hospitalization, stroke, heart failure, and unexpected coronary revascularization [including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)] because of clinical deterioration. All available relevant data from any reported possible event were collected. Death of a patient was reported by relatives or the general practitioners who treated the patient. Three experienced physicians who were masked to any of the study data independently classified the events.

**Statistical Analysis**

The values are expressed as the mean (standard deviation) for the continuous variables and as the number (percentage) for the categorical variables. Continuous variables and categorical variables were analyzed by the Student t test or χ² statistic test when appropriate.

To investigate the relation of ABO blood type to traditional cardiovascular risk factors (such as lipid profiles and inflammatory markers) as well as the presence and severity of CAD, Student t test or χ² statistic test was performed in the current study.

The event-free survival rates between O and non-O blood groups were estimated by the Kaplan–Meier method and compared by the log-rank test. The effect of ABO blood type on the occurrence of CVEs was evaluated using Cox proportional hazards models. Hazard ratio (HR) and 95% confidence interval (CI) were calculated for non-O (A, B, and AB) versus O blood type. The HR were adjusted for age in model 1, with additional adjustment for history of hypertension and DM in model 2, with additional adjustment for hs-CRP in model 3, and further excluded the potential influence of the severity of coronary atherosclerosis in model 4, all of which may confound the relationship between ABO blood type and CVEs. Patients were censored if they were lost to follow-up (4.4%).

The statistical analysis was performed with SPSS version 19.0 software (SPSS Inc., Chicago, IL). For all analyses, P < 0.05 was considered significant.

**TABLE 3. Univariate Cox Proportional Regression Analyses**

| Variable         | Hazard Ratio | 95% CI          | P Value |
|------------------|--------------|-----------------|---------|
| Age              | 1.016        | 1.005–1.027     | 0.004   |
| Sex              | 1.097        | 0.867–1.388     | 0.441   |
| BMI              | 0.994        | 0.962–1.028     | 0.730   |
| Hypertension     | 1.593        | 1.259–2.015     | <0.001  |
| Diabetes mellitus| 1.389        | 1.110–1.739     | 0.004   |
| Dyslipidemia     | 1.203        | 0.933–1.552     | 0.155   |
| hs-CRP           | 1.027        | 0.997–1.059     | 0.082   |
| Gensini score    | 1.011        | 1.008–1.013     | <0.001  |
| Non-O            | 1.320        | 1.033–1.685     | 0.026   |

Univariate Cox proportional regression analyses were performed. BMI = body mass index, CI = confidence interval, hs-CRP = high-sensitivity C-reactive protein.

**TABLE 4. Multivariate Cox Proportional Regression Analyses**

| ABO Blood Group | O | Non-O | P Value |
|-----------------|---|-------|---------|
| No. of events   | 85 (7.8%) | 263 (10.3%) |         |
| Median follow-up time, months | 24.4 | 24.6 |       |
| Age-adjusted HR (95% CI) | 1 | 1.313 (1.028–1.677) | 0.029 |
| Multivariated model 1 HR (95% CI) | 1 | 1.318 (1.030–1.685) | 0.028 |
| Multivariated model 2 HR (95% CI) | 1 | 1.304 (1.019–1.668) | 0.035 |
| Multivariated model 3 HR (95% CI) | 1 | 1.291 (1.005–1.659) | 0.046 |

Multivariate Cox proportional regression analyses were applied. Model 1: adjusted for age + history of hypertension, diabetes mellitus; Model 2: Model 1 + hs-CRP; Model 3: Model 2 + Gensini score. CI = confidence interval, HR = hazard ratio, hs-CRP = high-sensitivity C-reactive protein.
Cardiac Events During Follow-Up

The median period of follow-up was 24.6 months (interquartile range: 16.5–34.5 months). A total of 348 patients (9.1%) presented with CVEs during the follow-up period. Of these, 69 (19.8%) developed unstable angina pectoris, 32 (9.2%) suffered nonfatal myocardial infarction, 10 (2.9%) developed heart failure, 170 (48.9%) underwent myocardial revascularization procedures (PCI or CABG) because of clinical deterioration, 43 (12.4%) had strokes, and 24 (6.9%) died (18 cardiac death). Patients who suffered acute coronary syndrome (ACS) and underwent revascularization procedures were assigned once in the group with revascularization. As indicated in Supplemental Figure 2 http://links.lww.com/MD/A479, the non-O group had a significant higher prevalence of unstable angina pectoris (2.1% versus 1.1%, \( P = 0.035 \)), slightly higher cardiac death (0.6% versus 0.2%, \( P = 0.080 \)), and total death (0.8% versus 0.3%, \( P = 0.061 \)), whereas had similar percentage of nonfatal myocardial infarction (\( P = 0.874 \)), heart failure (\( P = 0.998 \)), revascularization (\( P = 0.234 \)), and stroke (\( P = 0.970 \)). More importantly, the percentage of total CVEs was significantly higher in the non-O blood group (10.3% versus 7.8%, \( P = 0.019 \)).

Relation of ABO With Risk Factors, Incidence, and Severity of Coronary Artery Disease

We next made this analysis to verify the relationship of non-O blood types with traditional risk factors as well as with CAD or myocardial infarction susceptibility and severity. In the current study, the traditional risk factors, such as the percentage of hypertension, DM, previous PCI or CABG, and family history of CAD were not statistically different between O and non-O groups (all \( P > 0.05 \)). Meanwhile, the prevalence of dyslipidemia was slightly higher in the non-O blood group (\( P = 0.062 \)). Given that lipid and inflammation were the established major contributors to cardiovascular disease, we further analyzed the link between ABO and lipid and inflammatory markers. Dramatically, we observed that the inflammatory markers including hs-CRP and ESR were higher in the non-O versus O blood groups (\( P = 0.003 \), both, Table 2). No significant differences, however, were found regarding the lipid profiles in the current analysis (\( P > 0.05 \), all, Table 2).

As indicated in Figure 1, the presence of CAD, myocardial infarction, and 3 vessels coronary disease was dramatically increased in the non-O blood groups (\( P = 0.011 \), \( P = 0.001 \), and \( P = 0.003 \), respectively). In addition, the non-O blood group had markedly higher Gensini score than the O group (\( P = 0.032 \)).

Non-O Blood Type and the Risk of Cardiovascular Events

As shown in Figure 2, patients with non-O blood groups had an increased risk of CVEs compared with those with O blood group (Fig. 2A). The Kaplan–Meier analysis demonstrated a significant difference in the event-free survival rate between non-O and O blood group (\( P = 0.026 \)). Among the 4 blood groups, the log-rank test for equality revealed that the event-free survival was statistically and significantly different (\( P \) for trend \( = 0.018 \), Fig. 2B).

In the Cox proportional hazard regression analysis, compared with patients with blood group O, those with blood group non-O were more likely to develop CVEs (HR = 1.320, 95% CI:
Simultaneously, we observed that age, hypertension, DM, hs-CRP, and Gensini score were all significant predictors of CVEs occurrence (HR = 1.016, 95% CI: 1.005–1.027; HR = 1.593, 95% CI: 1.259–2.015; HR = 1.389, 95% CI: 1.110–1.739; HR = 1.222, 95% CI: 1.000–1.493; and HR = 1.011, 95% CI: 1.008–1.013). Consequently, we further performed the multivariate adjustment for these potential risk factors. The data indicated that the associations between non-O blood groups and CVEs were not substantially altered in this analysis (multivariate-adjusted model 3, HR = 1.291, 95% CI: 1.005–1.659, Table 4). In addition, history of hypertension and Gensini score were both associated with significantly increased CVEs in the fully adjusted multivariate Cox regression analysis (Fig. 3A).

**DISCUSSION**

The current prospective study assessed the relation of ABO to risk factors and coronary severity, and more importantly, to future CVEs in 3823 Chinese Han patients with suspected or documented CAD who underwent elective coronary angiography. To the best of our knowledge, it is the first study deriving from a large cohort of Chinese Han population. As a result, we

| Study                                    | Study Design          | Study Patients               | Follow-Up Time | Endpoints                     | Summary Cardiovascular Risk of Non-O Blood Group-Associated (Adjusted HR or OR, 95% CI) |
|------------------------------------------|-----------------------|------------------------------|----------------|-------------------------------|------------------------------------------------------------------------------------------|
| For Risk of Cardiovascular Events        |                       |                              |                |                               |                                                                                          |
| Carpeggiani et al14                      | Prospective           | N = 4901, receiving coronary angiography | 10 years       | All-cause and cardiac mortality | 1.53 (1.06–2.21) (in <65 years) NS                                                    |
| Januszkiewicz et al23                    | Prospective           | N = 418, with ACS            | 69 months      | All-cause mortality           | NS                                                                                       |
| Etemadi et al12                          | Prospective           | N = 50,045, general population based | 6.9 years      | All-cause and cardiac mortality | 1.15 (1.03–1.27)                                                                         |
| Bakker et al13                           | Retrospective         | N = 4679, with major vascular surgery | 4 years        | Mortality                     | NS                                                                                       |
| Roest et al24                            | Prospective           | N = 200 (IHD)/1732 (control), women | NA             | MI                            | 1.8 (1.0–3.0)                                                                            |
| Jager et al25                            | Prospective           | N = 631, population based    | 5 years        | All-cause and cardiac mortality | 2.08 (0.85–5.07)                                                                         |
| Reilly et al26                           | Case-control (GWAS)   | N = 5783 (CAD + MI)/3644 (CAD but no MI) | NA             | MI                            | 1.62 (1.23–2.13)                                                                         |
| For Risk of Coronary Artery Disease       |                       |                              |                |                               |                                                                                          |
| Amirzadegan et al6                       | Cross-sectional       | N = 2026, underwent CABG     | NA             | CAD                           | NS                                                                                       |
| Lopez-Mejias et al29                     | Cross-sectional       | N = 2140, with rheumatoid arthritis | NA             | Subclinical and CVD           | NS                                                                                       |
| Gong et al8                              | Cross-sectional       | N = 2919, receiving coronary angiography | NA             | Severity of CAD               | A:1.44 (1.16–1.80)                                                                      |
| He et al11                               | Prospective           | N = 89,501, general population based | >20 years      | CAD                           | A:1.06 (0.99–1.15);                                                                      |
| B:1.15                                  |                       |                              |                |                               |                                                                                          |
| AB:1.23                                 |                       |                              |                |                               |                                                                                          |
| Sode et al27                             | Prospective           | N = 66,010, general population based | NA             | VTE, MI                       | 1.1 (1.0–1.1)                                                                           |

1.033–1.685, Table 3). Simultaneously, we observed that age, hypertension, DM, hs-CRP, and Gensini score were all significant predictors of CVEs occurrence (HR = 1.016, 95% CI: 1.005–1.027; HR = 1.593, 95% CI: 1.259–2.015; HR = 1.389, 95% CI: 1.110–1.739; HR = 1.222, 95% CI: 1.000–1.493; and HR = 1.011, 95% CI: 1.008–1.013). Consequently, we further performed the multivariate adjustment for these potential risk factors. The data indicated that the associations between non-O blood groups and CVEs were not substantially altered in this analysis (multivariate-adjusted model 3, HR = 1.291, 95% CI: 1.005–1.659, Table 4). In addition, history of hypertension and Gensini score were both associated with significantly increased CVEs in the fully adjusted multivariate Cox regression analysis (Fig. 3A). In the next analysis, we additionally examined the risk of CAD by comparing the A, B, and AB with the O blood type. Compared with patients reporting blood group O, those with A, B, and AB blood type had fully adjusted HR (95% CI) of 1.083 (0.797–1.472), 1.481 (1.122–1.955), and 1.249 (0.852–1.831), respectively (Fig. 3B).
observed that non-O blood group was associated with higher inflammatory markers, CAD susceptibility, and severity. Moreover, we found a significantly elevated risk of CVEs occurrence for patients with blood group non-O. The highest risk was observed for blood group B, followed by blood groups AB and A. The prognostic value of non-O blood group for future CVEs was not significantly modified by other known risk factors, including the baseline severity of coronary atherosclerosis. Our study adds to the current literature for providing further evidence for suggesting the pivotal role of non-O blood group in CVEs occurrence.

The association of non-O blood groups with the increased risk of cardiovascular disease has been recognized for some times.12 These observations have led a number of studies to investigate the relationship between ABO blood group and traditional risk factors and further postulate a mechanism whereby some of these associations with ABO operate through these risk factors. There is growing evidence that the ABO blood group is the major determinant of plasma VIII, von Willebrand factor, and thrombomodulin,15 which lead to increased thrombotic tendency. Recently, a series of genome-wide association studies have linked the ABO locus to the serum levels of soluble intercellular adhesion molecule-1, tumor necrosis factor α, and P-selectin,20,21 which are implicated in the atherosclerotic procession. Consistently, we also found that the non-O blood type had significantly higher inflammatory markers, such as hs-CRP and ESR levels in the current study, and may suggest the potential link between non-O and inflammation in promoting atherosclerosis. Furthermore, the non-O blood group has long been shown to correlate with higher total cholesterol and LDL-C levels,22 and the recent study proposed that approximately 10% of the effect of ABO blood group on CAD susceptibility was mediated by plasma cholesterol levels.23 Nonetheless, in our analysis, the plasma cholesterol levels were not statistically different between O and non-O groups although the percentage of dyslipidemia was slightly higher in the non-O group. This discrepancy was properly because of the influence of statin treatment. Besides that, we found that the non-O blood type was related to significantly higher presence of CAD and myocardial infarction, higher percentage of 3 vessels disease, and higher Gensini score, all of which were strong CVEs predictors.

The current data, however, were inconsistent regarding the association between non-O blood groups and increased cardiovascular risk because of the paucity of information from these studies (as shown in Table 5). A large-scale study combined the Nurses’ Health Study and the Health Professionals Follow-up Study cohort including a meta-analysis, non-O blood group had higher risk of CAD and 6.27% of the CAD patients were attributable to non-O blood groups.11 Nevertheless, this study was based on the general population and did not report all the CVEs. The recent published Golestan Cohort Study reported an increased mortality, particularly because of cardiovascular diseases in non-O blood groups,12 but the primary design of this study did not specific to cardiovascular disease. Although several cross-sectional as well as prospective studies have reported a higher cardiovascular risk in patients with blood group non-O,8,14,24–27 some others did not support this viewpoint.6,13,28,29 In light of the preceding discussion and the ethnic difference of ABO blood distribution, we performed this large-scale follow-up study in Chinese Han patients who underwent coronary angiography. Our study provided additional evidence for investigating the relationship between ABO and cardiovascular disease outcomes.

One limitation of our study is the observational and single-center design, whether the data can be used in more populations needs further investigations. Second, there was not enough cardiovascular mortality in this study to allow direct survival analysis. Third, the mechanism was not explored in the current study.

In summary, we observed higher inflammatory level and more severe coronary atherosclerosis in patients have non-O blood group. Specifically, our data for the first time suggested that non-O blood group was related to a higher CVEs occurrence. More importantly, this relationship remained significant even after adjusting for traditional and potential risk factors, including the inflammatory marker, hs-CRP, and the baseline severity of coronary atherosclerosis assessed by Gensini score.

REFERENCES

1. Whincup PH, Cook DG, Phillips AN, et al. ABO blood group and ischaemic heart disease in British men. Br Med J. 1990;300:1679–1682.
2. Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 1998;38:975–988.
3. Yamamoto F, Cid E, Yamamoto M, et al. ABO research in the modern era of genomics. Transfus Med Rev. 2012;26:103–118.
4. Wu O, Bayoumi N, Vickers MA, et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:62–69.
5. Gandara E, Kovacs MJ, Kahn SR, et al. Non-O blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost. 2013;110:1172–1179.
6. Amirzadegan A, Salarifar M, Sadeghian S, et al. Correlation between ABO blood groups, major risk factors, and coronary artery disease. Int J Cardiol. 2006;110:256–258.
7. Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–338.
8. Gong P, Luo SH, Li XL, et al. Relation of ABO blood groups to the severity of coronary atherosclerosis: an Gensini score assessment. Atherosclerosis. 2014;237:748–753.
9. Kaya A, Tanboga IH, Kurt M, et al. Relation of ABO blood groups to coronary lesion complexity in patients with stable coronary artery disease. Anadolu Kardiyol Derg. 2014;14:55–60.
10. Tanis B, Algra A, van der Graaf Y, et al. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol. 2006;77:67–73.
11. He M, Wolpin B, Rexzode K, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012;32:2314–2320.
12. Etemadi A, Kamangar F, Islami F, et al. Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. BMC Med. 2015;13:8.
13. Bakker EJ, Valetin TM, Hoeks SE, et al. ABO blood type does not influence the risk of cardiovascular complications and mortality after vascular surgery. Eur J Vasc Endovasc Surg. 2013;45:256–260.
14. Carpeggiani C, Cocceani M, Landi P, et al. ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study. Atherosclerosis. 2010;211:461–466.
15. Mazda T, Yabe R, NaThalang O, et al. Differences in ABO antibody levels among blood donors: a comparison between past and present
Japanese, Laotian, and Thai populations. *Immunohematology.* 2007;23:38–41.

16. Zhang Y, Xu RX, Li S, et al. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. *Nutr Metab Cardiovasc Dis.* 2015;25:426–433.

17. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. *Am J Cardiol.* 1983;51:606.

18. Zhang Y, Zhu CG, Guo YL, et al. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among Han Chinese population. *PLoS One.* 2014;9:e113460.

19. Jenkins PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? *Transfusion.* 2006;46:1836–1844.

20. Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. *Hum Mol Genet.* 2010;19:1863–1872.

21. Kiechl S, Pare G, Barbalic M, et al. Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. *Circ Cardiovasc Genet.* 2011;4:681–686.

22. Silbernagel G, Chapman MJ, Genser B, et al. High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis. *J Am Coll Cardiol.* 2013;62:291–299.

23. Chen Y, Chen C, Ke X, et al. Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. *Circ Cardiovasc Genet.* 2014;7:43–48.

24. Roest M, Voorbij HA, Barendrecht AD, et al. Risk of acute ischemic heart disease in postmenopausal women depends on von Willebrand factor and fibrinogen concentrations, and blood group genotype. *J Thromb Haemost.* 2007;5:189–191.

25. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. *Arterioscler Thromb Vasc Biol.* 1999;19:3071–3078.

26. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet.* 2011;377:383–392.

27. Sode BF, Allin KH, Dahl M, et al. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. *CMAJ.* 2013;185:E229–E237.

28. Januszkiewicz L, Szczerba E, Paszkowska P, et al. Association of blood groups with prognosis in acute coronary syndrome. *Pol Arch Med Wewn.* 2013;123:460–466.

29. Lopez-Mejias R, Genre F, Garcia-Bermudez M, et al. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. *Mediators Inflamm.* 2014;2014:756279.